Insilico Medicine inks deal worth $600 M with Takeda to advance strategic AI drug discovery

Hong Kong-based Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, has announced a strategi...

July 3, 2026 | Friday | News
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease

NeuroSense Therapeutics has reported positive biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC ...

June 26, 2026 | Friday | News
Innovative Molecules doses first patient in Phase 2a herpes trial

Innovative Molecules has dosed the first patient in its Phase 2a clinical trial evaluating adibelivir for recurrent geni...

June 26, 2026 | Friday | News
Servier enrols first US patient in rare paediatric epilepsy study

Servier has enrolled the first U.S. patient in a Phase Ib/II first-in-human clinical study evaluating an investigational...

June 26, 2026 | Friday | News
CeleCor submits FDA application for investigational heart attack drug

CeleCor Therapeutics has completed submission of its New Drug Application to the U.S. FDA for zalunfiban, its investigat...

June 25, 2026 | Thursday | News
Policy, Talent and Innovation Are Fueling Pennsylvania's Life Sciences Growth

During BIO 2026 in San Diego, BioSpectrum Asia spoke with Kurt Imhof, Senior Vice President, Policy & Public Affairs...

June 25, 2026 | Thursday | Influencers
Puerto Rico Is Reclaiming Its Place as a Global Biopharma Innovation and Manufacturing Hub

During the BIO International Convention 2026 (June 22–25) in San Diego, BioSpectrum Asia spoke with Lan Nguyen, Ch...

June 25, 2026 | Thursday | Influencers
The Smallest Arteries May Hold the Key to Some of Medicine’s Biggest Unmet Needs

While most cardiovascular research has traditionally focused on the heart and large blood vessels, a growing body of evi...

June 24, 2026 | Wednesday | Influencers
AustinPx CEO Elizabeth Hickman on Scaling Complex Oral Drugs Through the Thermo Fisher KinetiSol Collaboration

As the pharmaceutical industry advances towards increasingly complex, poorly soluble drug candidates, formulation has ...

July 5, 2026 | Sunday | Influencers
NVIDIA Announces BioNeMo Agent Toolkit

NVIDIA announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life scie...

June 24, 2026 | Wednesday | News
Haisco licenses oncology and complement candidates to Nuvectis

Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with U.S.-based biotechnology company Nuve...

June 24, 2026 | Wednesday | News
China's Abbisko deepens R&D collaboration with Eli Lilly for novel drug programmes

China-based Abbisko Therapeutics has entered into a strategic research collaboration and licence agreement with US-based...

June 24, 2026 | Wednesday | News
Lys Therapeutics raises over €25M to advance neurovascular antibody

Lys Therapeutics has raised more than €25 million since its founding in 2021 to advance LYS241, its lead neurovascu...

June 23, 2026 | Tuesday | News
SystImmune, Biokin secure first China approval for bispecific ADC iza-bren

SystImmune and parent company Sichuan Biokin Pharmaceutical have received regulatory approval in China for iza-bren, als...

June 23, 2026 | Tuesday | News
AnHorn secures US and Taiwan regulatory milestones for CIPN candidate

AnHorn Medicines has received U.S. FDA Investigational New Drug clearance and Taiwan Center for Drug Evaluation Index Ca...

June 23, 2026 | Tuesday | News
Korea's SK Biopharma collaborates with Insilico Medicine for $2.5 B AI-drug discovery deal

Insilico Medicine, a Hong Kong-based clinical-stage generative artificial intelligence (AI)-driven drug discovery compan...

June 22, 2026 | Monday | News
Japan's Axcelead DDP joins Eli Lilly TuneLab to advance AI drug discovery

Japan-based startup Axcelead Drug Discovery Partners (DDP), Inc. has entered a collaboration with Lilly TuneLab, a colla...

June 18, 2026 | Thursday | News
Insilico Begins Phase I Study of AI-Driven NLRP3 Inhibitor

Insilico Medicine has completed first-in-human dosing in the Phase I clinical study of ISM8969, an AI-driven small-molec...

June 18, 2026 | Thursday | News
Korea's LG AI Research, D&D Pharmatech partner to accelerate oral peptide drug discovery

South Korea-based LG AI Research has signed a master agreement with D&D Pharmatech for a joint next-generation oral ...

June 18, 2026 | Thursday | News
MindWalk Positions Biological Context Layer as AI Drug Discovery Bottleneck

MindWalk Holdings Corp. is positioning biological data infrastructure as a key bottleneck in AI-enabled drug discovery, ...

June 17, 2026 | Wednesday | News
Hillhurst Bio Doses First Subject in Phase 2a Parkinson’s Trial

Hillhurst Bio has dosed the first subject in its Phase 2a clinical trial evaluating HBI-002 for the treatment of Parkins...

June 16, 2026 | Tuesday | News
Genentech Gains FDA Priority Review for Oral SERD in Early Breast Cancer

Genentech has received U.S. FDA acceptance and Priority Review for its New Drug Application for giredestrant as an adjuv...

June 12, 2026 | Friday | News
Nuvalent Gains FDA Priority Review for ALK-Positive NSCLC Candidate

Nuvalent has received U.S. FDA acceptance and Priority Review for its New Drug Application for neladalkib in tyrosine ki...

June 11, 2026 | Thursday | News
Pfizer Secures FDA Approval for Expanded Hympavzi Use in Hemophilia

Pfizer has received US FDA approval for an expanded indication of Hympavzi for hemophilia A or B, broadening its use to ...

June 10, 2026 | Wednesday | News
Shionogi Receives US FDA Approval for Oral COVID-19 Post-Exposure Prophylaxis

Shionogi has received US FDA approval for XOCOVA, or ensitrelvir, as an oral post-exposure prophylaxis option for COVID-...

June 9, 2026 | Tuesday | News